Clinical Trials Logo

Carcinoid Tumor clinical trials

View clinical trials related to Carcinoid Tumor.

Filter by:

NCT ID: NCT00093782 Completed - Clinical trials for Metastatic Gastrointestinal Carcinoid Tumor

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Start date: December 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00088595 Completed - Carcinoid Tumors Clinical Trials

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Start date: January 2004
Phase: Phase 2
Study type: Interventional

Study evaluating SOM230 in patients with metastatic carcinoid tumors

NCT ID: NCT00075439 Completed - Insulinoma Clinical Trials

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Start date: December 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

NCT ID: NCT00056693 Completed - Clinical trials for Neuroendocrine Tumors

Treatment With SU11248 in Patients With Neuroendocrine Tumors

Start date: April 2003
Phase: Phase 2
Study type: Interventional

To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.

NCT ID: NCT00055809 Completed - Clinical trials for Metastatic Gastrointestinal Carcinoid Tumor

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Start date: January 2003
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PEG-interferon alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. Combining bevacizumab with PEG-interferon alfa-2b may kill more cancer cells

NCT ID: NCT00050349 Completed - Clinical trials for Neuroendocrine Tumors

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Start date: July 2002
Phase: Phase 2
Study type: Interventional

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid and other neuroendocrine tumors.

NCT ID: NCT00049023 Completed - Sarcoma Clinical Trials

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Start date: January 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. PURPOSE: This phase I trial is to study the safety and effectiveness of radiolabeled octreotide in treating children who have advanced or refractory solid tumors.

NCT ID: NCT00031681 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Start date: December 2001
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving 7-hydroxystaurosporine together with irinotecan hydrochloride may help kill more cancer cells by making tumor cells more sensitive to the drug.

NCT ID: NCT00027638 Completed - Lung Cancer Clinical Trials

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Start date: March 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.

NCT ID: NCT00019474 Completed - Pancreatic Cancer Clinical Trials

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

Start date: March 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person recover from the side effects of chemotherapy. Combining chemotherapy with interferon alfa may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and interferon alfa followed by filgrastim in treating patients who have gastrointestinal tract cancer.